Zhang Y-M, Fan J-K, Wang X-Y, Liu J, Li T, Wang X-S, Yang X-J
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
Eur Rev Med Pharmacol Sci. 2024 Nov;28(22):4591-4620. doi: 10.26355/eurrev_202411_36955.
This study aimed to investigate the expression levels of the MKNK2 gene in pan-cancer, its prognostic significance, and its relationship with the tumor immune microenvironment, as well as to assess its potential as an immunological and prognostic biomarker.
The research utilized data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE), including clinical and mutational information. Bioinformatic tools were employed to analyze the association of MKNK2 with carcinogenesis, including its links to prognosis, immune cell infiltration, tumor immune microenvironment, gene mutation, and the stemness of various tumor cells. A variety of statistical software and analytical tools were applied, including R software, SPSS 27.0, TIMER, CIBERSORT algorithm, and EPIC algorithm.
The study found that MKNK2 is abnormally expressed in pan-cancer and is associated with a poor prognosis. The levels of MKNK2 are highly related to immune cell infiltration and tumor stemness. Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration. Furthermore, the expression of MKNK2 shows significant correlations with immune cell infiltration, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and stemness scores across various cancers.
The abnormal expression of MKNK2 is associated with tumor progression, immune checkpoint genes, immune cell infiltration, microsatellite instability (MSI), tumor mutational burden (TMB), and stemness in a variety of tumors, especially in glioblastoma multiforme low-grade gliomas (GBMLGG). Therefore, MKNK2 may serve as a potent prognostic physiological marker and provide new avenues for the development of tumor mechanisms and therapeutic strategies targeting MKNK2 to enhance the efficacy of immunotherapy.
本研究旨在探讨MKNK2基因在泛癌中的表达水平、其预后意义及其与肿瘤免疫微环境的关系，并评估其作为免疫和预后生物标志物的潜力。
本研究利用了来自癌症基因组图谱（TCGA）、基因型-组织表达（GTEx）和癌细胞系百科全书（CCLE）的数据，包括临床和突变信息。采用生物信息学工具分析MKNK2与致癌作用的关联，包括其与预后、免疫细胞浸润、肿瘤免疫微环境、基因突变以及各种肿瘤细胞干性的联系。应用了多种统计软件和分析工具，包括R软件、SPSS 27.0、TIMER、CIBERSORT算法和EPIC算法。
研究发现MKNK2在泛癌中异常表达，并与不良预后相关。MKNK2的水平与免疫细胞浸润和肿瘤干性高度相关。值得注意的是，在肝细胞癌、多形性胶质母细胞瘤、低级别胶质瘤和急性髓系白血病中，MKNK2表达与临床结果和免疫浸润显示出强烈的相关性。此外，MKNK2的表达在各种癌症中与免疫细胞浸润、免疫检查点、肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）和干性评分显示出显著相关性。
MKNK2的异常表达与多种肿瘤的肿瘤进展、免疫检查点基因、免疫细胞浸润、微卫星不稳定性（MSI）、肿瘤突变负荷（TMB）和干性相关，尤其是在多形性胶质母细胞瘤低级别胶质瘤（GBMLGG）中。因此，MKNK2可能作为一种有效的预后生理学标志物，并为针对MKNK2的肿瘤机制和治疗策略的开发提供新途径，以提高免疫治疗的疗效。
